Acrivon Therapeutics, Inc. Common StockACRVNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +71.22% | +69.76% | +6.45% | +1.19% | +0.70% |
| Weighted Average Shares Diluted Growth | +71.22% | +69.76% | +6.45% | +1.19% | +0.70% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +42.18% | +46.32% | -31.23% | -32.32% | -34.02% |
| Book Value per Share Growth | -14.81% | -12.50% | -37.81% | -35.45% | -36.80% |
| Debt Growth | -21.51% | -20.94% | -22.70% | -25.52% | -25.68% |
| R&D Expense Growth | +19.56% | +37.03% | +7.70% | -29.24% | -17.90% |
| SG&A Expenses Growth | +13.43% | +0.86% | +0.86% | -3.78% | -15.09% |